Efficacy of Russia's second vaccine from coronavirus made 100 percent, - federal agency

Source : 112 Ukraine

The vaccine developed by Russian science institution Vector already passed two stages of clinical tests; two patients complained about pain in the injection site, otherwise no side effects were reported, Rospotrebnadzor says
18:00, 19 January 2021

Open source

The immunological efficiency of EpiVacCorona, the second registered Russian vaccine against coronavirus makes 100 percent. That's the evaluation of Rospotrebnadzor, Russia's Federal Agency for Health and Consumer Rights. Interfax news agency reported that on January 19.

"The vaccine's efficacy includes its immunological efficiency and profilactic efficiency. Based on the results of Phases 1 and 2 of clinical tests, immunological efficiency of EpiVacCorona makes 100 percent", reads the message released by press office of Rospotrebnadzor.

The first and second stage of clinical tests were performed from July to September 2020. During the second stage, two patients complained about pain in the injection site; in two days, the pain was gone. Otherwise no side effects were reported, Rospotrebnadzor said.

Related: Global inequality in Covid-19 vaccine distribution to lead to more virus mutations

In October 2020, Russian President Vladimir Putin announced that the new vaccine against coronavirus called EpiVacCorona was registered. The post-registration research began in November, with 150 volunteers aged above 60 and 3,000 aged below 18. 

EpiVacCorona is the second Russian vaccine against Covid-19. The first one, Sputnik V was registered in summer 2020; it is already employed by many countries worldwide. 

Related: Spain supports introduction of vaccination passports in EU

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more
latest news
editor's choice